Press Releases

Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia

May 03, 2022

Reviva Pharmaceuticals to Host Key Opinion Leader Webinar on Brilaroxazine for Schizophrenia and Other Neuropsychiatric Disorders

Apr 26, 2022

Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Mar 24, 2022

Reviva Pharmaceuticals Holdings, Inc. to Participate at the Maxim Virtual Growth Conference

Mar 22, 2022

Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences

Mar 18, 2022

Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights

Mar 15, 2022

Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia

Feb 01, 2022

Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of Schizophrenia

Jan 10, 2022

Reviva Pharmaceuticals to Participate in the Upcoming January Virtual Investor Conferences

Dec 20, 2021

Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Nov 15, 2021